Literature DB >> 6699189

Lymphoproliferations in the bone marrow: identification and evolution, classification and staging.

R Bartl, B Frisch, R Burkhardt, K Jäger, R Pappenberger, G Hoffmann-Fezer.   

Abstract

Bone marrow biopsies from 3229 patients with lymphoproliferative disorders and 1156 patients with benign or reactive lymphoproliferations were investigated and criteria for distinguishing between them are given. Bone marrow involvement was found in 89% of multiple myeloma, 64% of non-Hodgkin's lymphomas and 8% of Hodgkin's disease. According to the predominant proliferative cell type there were five major entities in multiple myeloma and non-Hodgkin's lymphomas: (1) plasmacytic; (2) lymphocytic; (3) hairy cell; (4) immunocytic; (5) centrocytic. These were further classified into distinct subtypes each of which had independent prognostic significance. The mode of spread of the lymphoproliferative disorders in the bone marrow showed one of six architectural patterns, which together with the quantity of infiltration in the biopsy (reflecting the tumour cell burden) had significant predictive value. These results demonstrate the value of bone marrow biopsies in the identification, classification and staging of lymphoproliferative disorders, as well as in monitoring the course of disease and the response to therapy.

Entities:  

Mesh:

Year:  1984        PMID: 6699189      PMCID: PMC498694          DOI: 10.1136/jcp.37.3.233

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  101 in total

1.  Clinical and surgical (laparotomy) evaluation of patients with non-Hodgkin's lymphomas.

Authors:  D R Goffinet; R Warnke; N R Dunnick; R Castellino; E Glatstein; T S Nelsen; R F Dorfman; S A Rosenberg; H S Kaplan
Journal:  Cancer Treat Rep       Date:  1977-09

Review 2.  Malignant lymphomas--a conceptual understanding of morphologic diversity. A review.

Authors:  R B Mann; E S Jaffe; C W Berard
Journal:  Am J Pathol       Date:  1979-01       Impact factor: 4.307

Review 3.  Non-Hodgkin's lymphomas: a clinicopathologic study comparing two classifications.

Authors:  B N Nathwani; H Kim; H Rappaport; J Solomon; M Fox
Journal:  Cancer       Date:  1978-01       Impact factor: 6.860

4.  Bone-marrow patterns and clinical staging in chronic lymphocytic leukaemia.

Authors:  A Carbone; A Santoro; S Pilotti; F Rilke
Journal:  Lancet       Date:  1978-03-18       Impact factor: 79.321

5.  Bone-marrow patterns and clinical staging in chronic lymphocyte leukaemia.

Authors:  D Charron; G Dighiero; M Raphael; J L Binet
Journal:  Lancet       Date:  1977-10-15       Impact factor: 79.321

6.  Morphology of lymphatic cells and of their derived tumours.

Authors:  F Rilke; S Pilotti; A Carbone; L Lombardi
Journal:  J Clin Pathol       Date:  1978-11       Impact factor: 3.411

7.  [Rational use of bone marrow biopsy. longitudinal hemisection of samples, for simultaneous adaption of various histological preparations without loss of material (author's transl)].

Authors:  R Bartl; R Burkhardt; H Vondracek; W Sommerfeld; E Hagemeister
Journal:  Klin Wochenschr       Date:  1978-06-01

8.  Blood and bone marrow findings in angioimmunoblastic lymphadenopathy.

Authors:  G A Pangalis; E M Moran; H Rappaport
Journal:  Blood       Date:  1978-01       Impact factor: 22.113

9.  Nodular lymphocytic lymphoma eventuating into diffuse histiocytic lymphoma: immunoperoxidase demonstration of monoclonality.

Authors:  B A Woda; D M Knowles
Journal:  Cancer       Date:  1979-01       Impact factor: 6.860

10.  Circulating lymphocytes and the spread of myeloma. Review of the evidence.

Authors:  T F Warner; R G Krueger
Journal:  Lancet       Date:  1978-06-03       Impact factor: 79.321

View more
  16 in total

1.  Incidence and histological features of bone marrow involvement in malignant lymphomas.

Authors:  G Lambertenghi-Deliliers; C Annaloro; D Soligo; A Oriani; E Pozzoli; N Quirici; R Luksch; E E Polli
Journal:  Ann Hematol       Date:  1992-08       Impact factor: 3.673

2.  Bone marrow trephine biopsy in lymphoproliferative disease.

Authors:  C Schmid; P G Isaacson
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

3.  Argyrophilic nucleolar organizer region counts in multiple myeloma: a histopathological study on bone marrow trephine biopsies.

Authors:  A Pich; L Chiusa; F Marmont; N Cappello; R Navone
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

4.  Reticulin fibre content of bone marrow infiltrates of malignant non-Hodgkin's lymphomas (B-cell type, low malignancy)--a morphometric evaluation before and after therapy.

Authors:  J Thiele; J Langohr; M Skorupka; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

5.  Plasma cell sarcoma in a cat.

Authors:  S A Mitcham; S R McGillivray; D M Haines
Journal:  Can Vet J       Date:  1985-03       Impact factor: 1.008

6.  Magnetic resonance imaging of bone marrow versus bone marrow biopsy in malignant lymphoma.

Authors:  M Ozgüroglu; G Esen Ersavasti; G Demir; H Aki; F Demirelli; K Kanberoglu; N Mandel; E Büyükünal; S Serdengeçti; B Berkarda
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

7.  Lymphoid aggregates in bone marrow: study of eventual outcome.

Authors:  B E Faulkner-Jones; A J Howie; B J Boughton; I M Franklin
Journal:  J Clin Pathol       Date:  1988-07       Impact factor: 3.411

8.  Differentiation of plasma cell infiltrates in the bone marrow. A clinicopathological study on 80 patients including immunohistochemistry and morphometry.

Authors:  J Thiele; B Arenz; H Klein; M Vierbuchen; R Zankovich; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

9.  Bone marrow trephine biopsy in lymphoproliferative disease.

Authors:  P W Bishop
Journal:  J Clin Pathol       Date:  1993-04       Impact factor: 3.411

10.  Demonstration of lymphoid antigens in decalcified bone marrow trephines.

Authors:  P A Hall; R Lindeman; M G Butler; J A Amess; A J D'Ardenne
Journal:  J Clin Pathol       Date:  1987-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.